CBIO Crescent Biopharma, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CBIO matters now
Crescent Biopharma, Inc. (CBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.34 with +3.46% on the session and $478.1M in market capitalization; recent performance reads 1-month -4.27% and YTD +49.16%.
The latest financial table shown here is Q1 2026, with revenue of $1.0M, net income of $-23.3M, and EPS of $-0.70. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.4%.
The latest indexable market news headline is "Crescent Biopharma Announces Grants of Inducement Awards" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.00; recent insider activity includes Fairmount Funds Management LLC filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.92
P/S
41.05
EV/EBITDA
-1.89
DCF Value
$20.86
FCF Yield
-30.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1372.9%
Net Margin
-1363.9%
ROE
-100.9%
ROA
-81.4%
ROIC
-87.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.0M | $-23.3M | $-0.70 |
| Q4 2025 | $10.8M | $-92.4M | $-4.01 |
| FY 2025 | $10.8M | $-153.9M | $-14.78 |
| Q3 2025 | $0.00 | $-24.6M | $-1.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.00
Target (Median)
$35.00
Target Range
$29.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.